THE Therapeutic Goods Administration (TGA) has advised that global shortages of most methylphenidate modified-release products have resolved, including Concerta modified-release tablets and Ritalin LA modified-release capsules.
Meanwhile, the shortages of all strengths of Rubifen LA capsules are expected to resolve by the end of Jun 2026.
Shortages of methylphenidate hydrochloride products over 2024 and 2025 were due in part to increased demand and affected multiple countries.
The TGA approved several overseas-registered modified-release capsule products to assist during this period, and these approvals remain in place until the end of this month.
Learn more HERE.
The above article was sent to subscribers in Pharmacy Daily's issue from 22 Apr 26
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 22 Apr 26
